A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.

Also called NCT05425056

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 136 participants (enrolled count) (from the registry)
Sponsor
Vascular Therapies, Inc. (from the registry)
Registry
  • NCT NCT05425056
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05425056. Randomized; triple masking; primary purpose prevention. Start 2022-08-26 (actual); primary completion 2025-03-18 (actual). Results posted on 2026-10-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery
Acronym
ACCESS2
Condition
Complication of Renal Dialysis
Condition
End Stage Renal Disease
Condition
End Stage Kidney Disease
Condition
ESRD
Condition
Chronic Kidney Failure
Condition
Complication of Hemodialysis
Condition
Vascular Access Complication
Condition
Arteriovenous Fistula
Intervention (Drug)
Sirolimus
Lead sponsor
Vascular Therapies, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05425056
Content hash
0fdc90a4b92bed070b457b4e8c85148c9e5d10d81d128cf0d75cc6172f65cdba